natgillin/translations-raw huggingface dataset:
If a size of the coding unit is equal to or larger than a minimum size of the quantization unit, the coding unit is set as the quantization unit. 
Postupak prema Zahtjevu 1, gdje je veličina transformacijske jedinice jednaka ili manja od 8x8, obrazac inverznog skeniranja se određuje na osnovi intrapredikcijskog režima.
The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, which is represented by the following formula: {wherein Z1 represents -O- or -NR11- (wherein R11 represents hydrogen or C1-C6 alkyl), p represents an integer of 0 to 3, r represents an integer of 0 to 2, and R3 represents halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy or oxo}. 
Derivat fenilpirazola ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da je prikazan sa slijedećom formulom: [image] pri čemu Z1 predstavlja -O- ili -NR11- (pri čemu R11 predstavlja vodik ili C1-C6 alkil), p predstavlja cijeli broj od 0 do 3, r predstavlja cijeli broj od 0 do 2, i predstavlja halogen, C1-C6 alkil, C1-C6 alkoksi, hidroksi ili okso.
using the presence or degree of such binding as a measure of the presence of nucleosomes containing the DNA base in the body fluid sample, wherein the DNA base is selected from: 5-methylcytosine or 5-hydroxymethylcytosine. 
(iv) korištenje prisutnosti ili stupnja takvog vezanja kao mjere prisutnosti nukleosoma koji sadrže bazu DNK u uzorku tjelesne tekućine, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
reacting the compound of Formula XXX with a compound of Formula XV R1-B(OH)2 Formula XV to give a compound of Formula XXXI; hydrogenating the compound of Formula XXXI to give a compound of Formula XXXII; 
R1-B(OH), Formula XV čime se dobiva spoj Formule XXXI: Formula XXXI hidrogeniranje spoja Formule XXXI, čime se dobiva spoj Formule XXXII:
by suitable sensing means. 
pogodna osjetila.
linkage systems (4) pivoting in a plane parallel to the longest sides of the frame (2) respectively arranged at each of the 4 corners of the frame (2) and fixedl thereto, 
(1i) 4 vezna sustava (4) koji se mogu okretati u ravnini koja je paralelna sa najduljim stranicama okvira (2) koji su postavljeni na svakom od 4 kuta okvira (2) te su na njega učvršćeni,
According to the invention, user-defined indicia are engraved into at least one surface of the said body of permanent-magnetic composite material. The engraving can hereby take place either before or after the magnetization operation. 
Sukladno predmetnom izumu, oznaka koju izrađuje korisnik se ugravira u najmanje jednu površinu navedenog tijela permanentno magnetskog kompozitnog materijala, Graviranje se može izvršiti prije ili nakon postupka magnetizacije.
A pharmaceutical composition for use according to claim 2 wherein the oncological disease is selected from the group consisting of urogenital cancers, lung cancers, gastrointestinal cancers, head and neck cancer, malignant mesotheliomas, breast cancer, malignant melanoma, childhood cancers, and bone or soft tissue sarcomas. 
Uporaba u skladu sa zahtjevom 11, naznačena time, da onkološko oboljenje je izabrano iz skupine koju čine urogenitalni karcinomi, plućni karcinomi, gastrointestinalni karcinomi, karcinom glave i vrata, maligni mezoteliomi, karcinom dojke, maligni melanom, karcinomi kod djece te sarkomi kosti ili mekog tkiva.
The extended release dosage form of claim 15, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride. 
Postupak prema zahtjevu 39, naznačen time da je opioidni analgetik oksikodon hidroklorid i da oblici davanja sadrže od oko 5 mg do oko 500 mg oksikodon hidroklorida.
The polypeptide of claim 2 or 3, wherein the polypeptide has a formula selected from the group consisting of: A-F1-B-P1-L-P2-F2; A-F1-P1-L-P2-B-F2; A-F1-P1-L-P2-F2; and F1-P1-L-P2-B-F2; in linear sequence from amino to carboxy terminus, and wherein A is the at least one biologically active moiety; 
Polipeptid prema patentnom zahtjevu 2 ili 3, naznačen time što polipeptid ima formulu izabranu iz skupine koja se sastoji od: A-F1-B-P1-L-P2-F2; A-F1-P1-L-P2-B-F2; A-F1-P1-L-P2-F2; i FI-P1-L-P2-B-F2; u linearnoj sekvenci od amino do karboksi terminalnog kraja, i pri čemu A je barem jedan biološki aktivan dio;
said at least one corticosteroid comprises prednisone and said at least one non-corticosteroid chemotherapeutic agent comprises bortezomib; or 
spomenuti najmanje jedan kortikosteroid obuhvaća prednison i spomenuto najmanje jedno ne-kortikosteroidno kemoterapeutsko sredstvo obuhvaća bortezomib; ili
The process of Claim 5, wherein the amide is the N,N-dialkylformamide; and the conditions suitable for forming the amide solvate of the compound of formula II comprise a temperature of between about 20 °C and about 70 °C; preferably wherein: the amide is N,N-dimethylformamide (DMF); and the conditions suitable for forming the amide solvate comprise re-slurrying of the acid solvate in the DMF at a temperature of about 50 °C. 
Postupak prema zahtjevu 5, naznačen time da amid je N,N-dialkilformamid; te pogodni uvjeti za nastanak amidnog solvata spoja s formulom II obuhvaćaju temperaturu od između oko 20 "C i oko 70 "C; poželjno pri čemu: amid je N,N-dimetilformamid (DMF); i t pogodni uvjeti za nastanak amidnog solvata obuhvaćaju ponovno suspendiranje kiselog solvata u DMF kod temperature od oko 50 "€.
Purification by chromatography on silica gel eluting with a mixture of dichloromethane/methanol/aqueous ammonia solution (29%) in the proportions 100/0/0 to 70/30/3 led to compound in the form of an oil (2.86g). 
Pročišćavanje kromatografijom na silikagelu, uz eluiranje smjesom diklormetan/metanol/vodena otopina amonijaka (29 %), u odnosima od 100/0/0 do 70/30/3, daje spoj u obliku ulja (2,86 g).
The bispecific antibody or antibody fragment or the pharmaceutical composition according to claim 13, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Bispecifično protutijelo ili fragment protutijela za uporabu prema zahtjevu 14, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, sklerodermija i idiopatska plućna fibroza.
an entropy decoding unit (210) configured to restore an intra prediction mode and one-dimensional (1D) quantized coefficients; 
Uređaj za dekodiranje slike, uređaj sadrži: jedinicu za dekodiranje entropije (210) konfiguriranu za vraćanje načina unutarokvirnog predviđanja i jednodimenzionalne (1D) kvantizirane koeficijente;
The device according to claim 1, wherein said engravings in said body of permanent-magnetic material are filled up with a magnetic material. 
Uređaj sukladno jednom od patentnih zahtjeva 1 do 4, naznačen time, da su navedene gravure u navedenom tijelu ispunjene magnetskim materijalom.
an at least partially straight shaft (108) defining a z axis (116); 
- barem djelomično ravnu osovinu (108);
Drug-containing layers containing 1.9 mg of Gestodene and 0.9 mg of Ethinylestradiol and composed of different mixtures of polymers are shown (A to M). A composition for transdermal delivery comprising a drug-containing layer that comprises Gestodene or an ester thereof and a carrier selected from the group consisting of polyisobutylenes, polybutenes, polyisoprenes, polystyrenes, styrene isoprene styrene block polymers, styrene butadiene styrene block polymers and mixtures thereof, wherein the drug-containing layer has a solubility for said Gestodene of no more than 3% by weight of the drug-containing layer, and wherein the Gestodene or an ester thereof is present in an amount ranging between 0.5 and 3% by weight of the drug-containing layer. 
Pripravak za transdermalno davanje, naznačen time, da sadrži sloj koji sadrži lijek, a koji uključuje Gestoden ili neki njegov ester i nosač koji je odabran iz skupine koja se sastoji od poliizobutilena, polibutena, poliizoprena, polistirena, stiren izopren stiren blok polimera, stiren butadien stiren blok polimera i njihovih mješavina, pri čemu sloj koji sadrži lijek ima topivost za navedeni Gestoden od ne više od 3% težine samoga sloja koji sadrži lijek i pri čemu Gestoden ili neki njegov ester je prisutan u količini u rasponu između 0.5 i 3% težine samoga sloja koji sadrži lijek.
Live cells were counted using a hemacytometer and Trypan blue exclusion, and the cell concentration was adjusted to 2x106 cells/ml. 
Žive stanice su prebrojane uporabom hemacitometra i Tryptan plavila, te je koncentracija stanica namještena na 2 x 10* stanica/ml.
A process for reducing the amount of 14-hydroxycodeinone in an oxycodone hydrochloride composition to a level of less than 25 ppm as determined by the HPLC method of Example 6, the process comprising reacting the oxycodone hydrochloride composition with a catalytically effective amount of a palladium-carbon catalyst and hydrogen gas, thus hydrogenating the 14-hydroxycodeinone. 
Postupak za pripremu sastava oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm dovođenjem sastava oksikodonske baze koji ima spoj 8,14-dihidroksi-7,8-dihidrokodeinona u reakciju s klorovodičnom kiselinom, pri čemu je 8,14-dihidroksi-7,8-dihidrokodeinon preveden u 14-hidroksikodeinonom, i reduciranjem 14-hidroksikodeinona u oksikodon.
According to the present invention, the amount of water dispersible form of titanium dioxide in the composition is about 0.04%, 0.0425%, 0.0525%, 0.0625%, 0.0725%, or 0.08% (w/w). 
Kompozicija topičkog gela prema zahtjevu 1, pri čemu ukupni poliol sadrži oko 4,5% do 6,5% (w/w) prvog poliola.
The method of claim 1, wherein said dosage form comprises a pharmaceutically acceptable salt of paroxetine. 
2. - Paroksetin za upotrebu prema patentnom zahtjevu 1, naznačen time što je paroksetin u kristalnom obliku.
wherein the disintegrant is crospovidone or a mixture of crospovidone and calcium silicate. A pharmaceutical composition comprising: 
krospovidon i kalcijev silikat: 2-20% (w/w), u odnosu na masu tableta.
R6b is hydrogen, or together with R7b a -CH2 group, or a double bound; 
RS je vodik, ili zajedno s R? je skupina -CH,, ili dvostruko vezan;
Stirring was continued at room temperature for 1.5 hours then the solvent removed by evaporation under reduced pressure. 
S miješanjem se nastavi 1,5 sati na sobnoj temperaturi, a otapalo se ukloni otparavanjem pod sniženim tlakom.
The pharmaceutical composition of claim 1, wherein said composition is formulated as a liquid formulation in the form of a nasal spray or nasal drops. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran kao tekuća formulacija u obliku nazalnog spreja ili nazalnih kapi.
two opposed first side members (3, 4) are provided with grips (3b, 4b), and 
dva nasuprotna prva bočna dijela (3, 4) imaju ručke (3b, 4b), i
A sample from a batch of immunopurified r-hIL-18BP-His was used as reference sample during the development of the assay. 
Uzorak 1z šarže imunopročišćenog T-hIL- 18BP-His korišten je kao referentni uzorak tijekom razvoja testa.
A dicyclohexylamine salt of perindopril as claimed in claim 1 having an X-ray diffractogram, or substantially the same X-ray diffractogram, as set out in Figure 1. 
MO Dicikloheksilamin sol perindoprila prema zahtjevu 1, koja ima difraktogram X-zraka, ili u biti isti difraktogram X-zraka, kao što je prikazano na slici 1.
washing with a solution comprising SSC and NP40, wherein the cell sample is in the form of a cell suspension. 
I) pranje otopinom koja sadrži SSC 1 NP40, pri čemu je stanični uzorak u obliku stanične suspenzije.
R6/2 transgenic mice exhibit a progressive neurological phenotype that mimics many of the features of Huntington's disease, including choreiforin-like movements, involuntary stereotypic movements, tremor and epileptic seizures. 
R6/2 transgenski miševi pokazuju progresivni neurološki fenotip koji oponaša mnoge značajke Huntington-ove bolesti, uključujući pokrete slične koreji, nehotične stereotipne pokrete, drhtavicu i epileptičke napadaje.
The process according to claim 1, wherein said salt of a fatty acid is selected from the group consisting of magnesium stearate, sodium stearyl fumarate, sodium stearyl lactylate, sodium lauryl sulfate, and magnesium lauryl sulfate. 
Postupak prema patentnom zahtjevu 1, naznačeno time da je sol masne kiseline odabrana iz skupine koju čine magnezijev stearat; natrijev stearil-fumarat; natrijev stearil-laktilat; natrijev lauril-sulfat, te magnezijev lauril-sulfat.
delumping the extragranular lubricant using a suitable screen/mill and blend with granules from step (4); 
uklanjanje grudica iz ekstragranularnog lubrikanta uporabom sita ili mlina i miješanje sa granulama iz koraka (4);
an isolated polynucleotide comprising a sequence encoding a heavy chain of an antibody having the amino acid sequence of SEQ ID NO:176 or 178. 
izolirani polinukleotid koji sadrži slijed koji kodira teški lanac protutijela koji ima aminokiselinski slijed SEQ ID NO: 176 ili 178.
A pharmaceutical formulation according to claim 7 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 3, naznačen time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
imazamox a s well as its respective environmentally compatible salts or esters or amides or other derivatives; and metazachlor and quinmerac including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
Sinergijska herbicidna smjesa prema zahtjevima 1 do 2 gdje se sulfonamid izabire iz grupe koja obuhvaća florasulam, flumetsulam, metosulam, penoksulam, kloransulam-metil, i diklosulam, uključujući njihove odgovarajuće izomere kao i odgovarajuće, prihvatljive za okoliš, soli ili estere ili amide ili druge derivate.
scaling of the estimated offset as a function of the ratio between the first and second transmission operating frequencies. 
- - određivanje veličine očekivanog odašiljanja kao funkcije raspona između prve (f;) i druge (f:) operativne frekvencije emitiranja.
The present invention also relates to computer program product to enhance high availability in a telecommunications network, the computer program product comprising a computer program stored on a storage medium, the computer program comprising program code which, when executed on a computer, causes the computer to perform an inventive method according to the present invention. 
Računalni programski proizvod za poboljšanje visoke dostupnost u telekomunikacijskoj mreži (10), računalni programski proizvod koji sadrži računalni program pohranjen na memorijskom mediju, računalni program koji sadrži programski kod koji, kada se izvršava na računalu, uzrokuje da računalo obavlja metodu prema jednom od zahtjeva 1 do 10.
A combination therapy consisting of (a) DMF and/or MMF, and (b) interferon-beta, for use in treating a subject having MS. 
Kombinacijska terapija koja se sastoji od (a) DMF i/ili MMF i (b) interferona-B, naznačena time što je namijenjena upotrebi u liječenju subjekta koji ima MS.
A compound of Claim 1, wherein R3 is selected from the group consisting of cyano, nitro, 
Spoj prema Zahtjevu 1, naznačen time, da R, je odabran iz skupine koja sadrži (1) cijano,
Use of 2-aminoethanol as an additive in an aqueous suspension, containing from 48 to 62 vol. 
Uporaba 2-aminoetanola kao aditiva u vodenim suspenzijama koje sadrže od 25 do 62 vol.
Such other active ingredients may be a NSAID, a NO-releasing NSAID, a COX-2 inhibitor or a bisphosphonate. 
Takvi drugi aktivni sastojci mogu biti NSAID, NO-oslobađajući NSAID, inhibitor COX-2 ili bisfosfonat.
A pyrimidone derivative represented by formula (III) wherein R1, R2, R3, R4, R5, R6, R7, m and o are as defined for compound of formula (I) according to claim 1. 
Derivat pirimidona prikazan formulom (III) [image] naznačen time što R1, R2, R3, R4, R5, R6, R7, m i o su definirani kao za spoj formule (I), u skladu s patentnim zahtjevom 1.
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, hepatitis B, 2, 3 or 5 acellular Bordetella pertussis antigens and also inactivated type 1, 2 and 3 polioviruses. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, antigenima hepatitisa B, 2, 3 ili 5 acelularnih antigena Bordetella pertussis i također inaktiviranim tipovima 1, 2 i 3 poliovirusa.
Clearly there is a need for new antiviral agents, preferably targeting other viral enzymes to reduce the rate of resistance and suppress viral replication even further. 
Jasno je da ovdje postoji potreba za novim antivirusnim sredstvima, koja poželjno ciljno djeluju na druge virusne enzime da bi se smanjila stopa otpornosti i čak dodatno suprimirala virusna replikacija.
The method of claim 21 further comprising inserting at least one second recombinant nucleic acid molecule into the Mycobacterium cell, said second recombinant nucleic acid molecule encoding a peptide or polypeptide capable of eliciting an immune response in a mammal. 
Postupak prema zahtjevu 28, naznačen time što obuhvaća umetanje (inserciju) najmanje jedne dodatne rekombinantne molekule nukleinske kiseline u bakterijsku stanicu, a ta dodatna rekombinantna molekula nukleinske kiseline kodira peptid ili polipetid koji ima sposobnost izazvati imuni odgovor kod sisavca.
Furthermore, various foreign ions from the group of the halogens, non-metals, alkaline and alkaline earth metals, and representatives of the transition metals and semimetals and metals can be incorporated into the crystal structure of the phase. These are all suitable for the ternesite clinker. Phosphate, fluoride, borium, nitrate, chloride, sodium and/or potassium, for example, are preferably incorporated into the structure of C5S2$ for the stabilization thereof (e.g. at high temperatures >1200° C.). 
Postupak sukladno zahtjevu 1 ili 2, naznačen time što C5S2$ je stabiliziran dodavanjem jednog ili više stranih iona iz skupine halogena, nemetala, alkalijskih i zemnoalkalijskih metala kao i supstanci iz skupine vodiča i metaloida i metala kristalne strukture. Postupak sukladno barem jednom od zahtjeva 1 do 3, naznačen time što materijali, koji opskrbljuju mineralizatore, poželjno fosfati, fluoridi, alkali, nitrati i/ili kloridi, dodaju se sirovoj smjesi.
Also disclosed is a maize plant cell, tissue or plant comprising one or more copies of a SCBV enhancer element shown in position 337 to position 618 of SEQ ID NO: 1. In one embodiment, a maize plant cell, tissue or plant comprises one or more copies of a SCBV enhancer element shown in position 337 to position 618 of SEQ ID NO: 1 in which the one or more copies of the SCBV enhancer element is inserted into a genome of the maize plant cell, tissue or plant at a random location. In some embodiments, the SCBV enhancer imparts enhanced transcription of a nucleotide sequence of interest which is under regulatory control of the SCBV enhancer as compared to transcription of the nucleotide sequence of interest in the absence of the SCBV enhancer. 
Biljna stanica kukuruza, tkivo ili biljka kukuruza, naznačena time, da obuhvaća kimerno regulacijsko područje transkripcije koje obuhvaća jednu ili više kopija elemenata pojačivača virusa šećerne trske bacilnog oblika (SCBV- pojačivača) prikazanog na poziciji 337 do pozicije 618 od SEQ ID NO: I, ili njegov homolog koji ima najmanje 90% identiteta s pozicijom 337 do pozicije 618 od SEQ ID NO: I; 1 s time operativno povezan jedan heterologni promotor koji obuhvaća mjesto vezanja RNK polimeraze i mjesto inicijacije mRNK, gdje se kimerno regulacijsko područje transkripcije uvodi u genom biljne stanice kukuruza, tkivo ili biljku kukuruza na nasumičnim mjestima. Biljna stanica kukuruza, tkivo ili biljka kukuruza prema zahtjevu 14, naznačena time, da SCBV-pojačivač dodjeljuje pojačanu transkripciju interesne nukleotidne sekvence koja je pod regulacijskim upravljanjem SCBV- pojačivača, u usporedbi s transkripcijom interesne nukleotidne sekvence u odsutnosti SCBV -pojačivača.
The system according to claim 11, wherein the hydrogel is a co-polymer of polysulfonate and acrylic acid. 
Sustav prema patentnom zahtjevu 7 dio (c), naznačen time što je hidrogel kopolimer polisulfonata i akrilne kiseline.
A method for the treatment of cancer, which comprises administering to a subject in need thereof a therapeutically-effective amount of the compound or a salt or N-oxide derivative thereof as claimed in claim 1, in combination with radiation therapy. 
Tvar ili bilo kojeg od patentnih zahtjeva 1 do 12 ili farmaceutski prihvatljiva sol ili njen N-oksid derivat ili kombinacija iz patentnog zahtjeva 14 za uporabu u kombinaciji s terapijom zračenjem.
The process according to any one of claims 1 to 16, characterized in that the treatment process of step c) is a wet treatment process, wherein the obtained aqueous suspension is preferably dried, thereby obtaining the surface-treated calcium carbonate in the form of granules or a powder. 
Postupak prema bilo kojem zahtjevu od 1 do 16, naznačen time da je postupak obrade iz koraka c) vlažni postupak obrade, pri čemu je poželjno dobivena vodena suspenzija osušena, te se tako dobiva površinski obrađen kalcijev karbonat u obliku granula ili praha. HR P20130014 T1
In a preferred embodiment, the amino acid substitution in position 10 is P10Q and the amino acid substitution in position 32 is K32E 
Varijanta iz bilo kojeg prethodnog zahtjeva, naznačena time, da nadalje sadrži amino kiselinsku supstituciju u položaju 10 i/ili 32.
The compound of claim 6, wherein X41 is NR42 and X42 is N. 
Spoj prema zahtjevu 19, pri čemu je Xxje NR4x 1 Xp je N.
For the development and supply of biologically active products, such as therapeutic proteins or vaccines, large amounts must be produced. 
Za razvoj i opskrbu biološki aktivnim produktima, poput terapeutskih proteina ili cjepiva, nužno je proizvesti ih u velikim količinama.
The arrester according to claim 15, characterized in that the hollow component of the insulating body and the additional electrode have circular cross-sections. 
Gromobran u skladu s patentnim zahtjevom 15, naznačen time što šuplja komponenta izolirajućeg tijela (1) i dodatna elektroda (7) imaju kružni poprečni presjek.
The process according to para 1 wherein the ketoreductase in step (c) affords an enantiomeric excess at least about 98%. 
Postupak prema zahtjevu 1, naznačen time, da ketoreduktaza u koraku (c) donosi enantomerni višak od najmanje oko 98%.
Summary of the invention The present invention provides stable, recombinant, pre-fusion respiratory syncytial virus (RSV) fusion (F) polypeptides, i.e. recombinant RSV F polypeptides that are stabilized in the pre-fusion conformation. 
Rekombinantni prefuzijski respiratorni sincicijski virus (RSV) fuzijski (F) polipeptid, koji sadrži najmanje jedan epitop koji je specifičan za prefuzijski konformacijski F protein, pri čemu se najmanje jedan epitop prepoznaje pomoću prefuzijskog specifičnog monoklonskog protutijela, koje sadrži CDRI regiju teškog lanca iz SEQ ID NO:
secondary phases 0 to 30% by weight, 
0 do 25% po težini sekundarne faze
The mouse of claim 15, wherein the mouse further comprises at an endogenous B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide. 
Miš prema zahtjevu 8 ili 12, naznačen time, da miš nadalje na endogenom fB2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid.